Diroximel Fumarate
DrugAdministered as specified in the treatment arm.
Other names: VUMERITY, BIIB098
NCT Number: NCT05658497
The primary objectives of the study are to estimate the risk of major congenital malformations (MCMs) in infants born to women with multiple sclerosis (MS) who were exposed to diroximel fumarate (DRF) at any time from 2 weeks after the first day of their last menstrual period (LMP) up through the first trimester of pregnancy and to comparatively evaluate pregnancy outcomes with MCMs in women with MS who were exposed to DRF at any time from 2 weeks after the first day of their LMP through the first trimester of pregnancy with the following: i) women with MS who were unexposed to disease modifying therapies (DMTs) and, ii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries).
The secondary objective of the study is to evaluate pregnancy outcomes in women with DRF exposure at any time from 2 weeks after the first day of their LMP through the end of pregnancy compared with the following: i) women with MS who were unexposed to DMTs, ii) women with dimethyl fumarate (DMF) exposure, iii) women with MS who were exposed to other DMTs (e.g., Avonex and Tysabri Pregnancy Registries), and iv) women without MS (e.g., women from external, general population comparators).
Interested in participating?
Request InfoFemale
Observational
Austin Hospital, Heidelberg, Australia
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion criteria may apply
Administered as specified in the treatment arm.
Other names: VUMERITY, BIIB098
Administered as specified in the treatment arm.
Other names: BG9418, interferon beta-1a
Administered as specified in the treatment arm.
Other names: Natalizumab, BG00002
Administered as specified in the treatment arm.
Other names: Tecfidera, DMF, BG00012
Time frame: Up to 52 weeks postdelivery
MCMs include abnormalities in structural development that are medically or cosmetically significant are present at birth, and persist in postnatal life unless or until repaired as evaluated by independent advisors used throughout the registry.
Time frame: Up to 9 months of pregnancy
Elective or therapeutic pregnancy termination is any induced or voluntary fetal loss during pregnancy. It will be subclassified as elective or therapeutic pregnancy terminations as whether it was due to a fatal anomaly or not.
Time frame: Before 22 weeks of gestation
Spontaneous abortion is defined as any loss of a fetus due to natural causes before 22 weeks of gestation.
Time frame: At or after 22 weeks of gestation
Fetal death or stillbirth refers to the death of a fetus prior to complete expulsion or extraction from its mother at or after 22 weeks of gestation. Death is indicated by the fact that, after such separation, the fetus does not show any evidence of life (e.g., heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles). Fetal death occurring at or after 22 weeks but before 28 weeks of gestation is considered an early fetal loss. Fetal death occurring at or after 28 weeks is considered a late fetal loss.
Time frame: Up to delivery (approximately 10 months)
A live birth refers to a complete expulsion or extraction from its mother of a surviving neonate breathing, or showing any other evidence of life, such as heartbeat, umbilical cord pulsation, or definite movement of voluntary muscles, whether the umbilical cord has been cut or the placenta is attached. Any live birth before 37 weeks of gestation will be considered premature birth. Any live birth at or after 37 weeks but before 42 weeks of gestation will be considered full-term birth. Any live birth at or after 42 weeks of gestation will be considered post-term birth.
Time frame: Up to 9 months of pregnancy
Time frame: Up to 9 months of pregnancy
Time frame: Up to 12 weeks postdelivery
Maternal death is death of a pregnant woman during pregnancy, labor, or delivery. Registry will also report maternal deaths that occur up to 12 weeks postdelivery.
Time frame: Prior to 28 days postdelivery
Neonatal death is death occurring in a neonate prior to 28 days of life.
Time frame: At or after 28 days to 12 weeks postdelivery
Perinatal death is death occurring at or after 28 days of life and prior to 12 weeks of life.
Time frame: Between 12 to 52 weeks postdelivery
Infant death is death occurring between 12 and 52 weeks of life, inclusive.
Time frame: Up to 52 weeks postdelivery
Time frame: Up to 52 weeks postdelivery
Infant growth measurements will be used to estimate gender-specific weight-for-length, head circumference-for-age, length-for-age, and weight-for-age percentiles. Developmental milestones (i.e., social/emotional, language/communication, neurocognitive, movement/physical development) will be used to determine results of infant status (i.e., below, above, or at age-appropriate achievement).
Time frame: Up to 9 months of pregnancy
Pregnancy complications may include incidences of pre-eclampsia, eclampsia, pregnancy-induced hypertension, preterm labor, gestational diabetes and placenta previa.
Contact information is provided by the study sponsor or research team.
Global Biogen Clinical Trial Center
CONTACT
US Biogen Clinical Trial Center
CONTACT
Biogen
Industry
Vumerity (Diroximel Fumarate) Prospective MS Pregnancy Exposure Registry
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03816345
Arthritis, Arthritis, Psoriatic
Birmingham, Alabama, United States
View Trial DetailsNCT07736482
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Afyonkarahisar, Merkez, Turkey (Türkiye)
View Trial DetailsNCT07738978
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Cleveland, Ohio, United States
View Trial DetailsNCT07738120
Autoimmune Diseases, Autoimmune Diseases of the Nervous System
Pontevedra, Spain
View Trial Details